Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stewart A Factor

Showing results (131-140 of 198) with videos related to

Pageof 20
Sort By:
Parkinsonism & Related Disorders|July 25, 2013
Sleep and impulsivity in Parkinson's diseaseMichael K Scullin, Ann B Sollinger, Julia Land, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 21, 2023
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and RecommendationsDavide Martino, Vikram Karnik, Roongroj Bhidayasiri, et al.
Frontiers in Neurology|November 30, 2016
A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical DystoniaCecília N Prudente, Randall Stilla, Shivangi Singh, et al.
American Journal of Human Genetics|November 5, 2013
Association of Parkinson disease with structural and regulatory variants in the HLA regionWilliam T Wissemann, Erin M Hill-Burns, Cyrus P Zabetian, et al.
Parkinsonism & Related Disorders|December 3, 2020
A metabolomic study of cervical dystoniaChang Liu, Laura Scorr, Gamze Kilic-Berkmen, et al.
Journal of the Neurological Sciences|December 4, 2014
Cognitive correlates of hallucinations and delusions in Parkinson's diseaseStewart A Factor, Michael K Scullin, Ann B Sollinger, et al.
The Lancet. Neurology|December 11, 2019
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 studyC Warren Olanow, Stewart A Factor, Alberto J Espay, et al.
Journal of Clinical Psychopharmacology|June 20, 2024
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Frontiers in Neurology|March 14, 2022
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Annals of Neurology|December 26, 2006
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patientsDenise M Kay, Dawn Moran, Lina Moses, et al.
Pageof 20

Showing results (131-140 of 198) with videos related to

Sort By:
Pageof 20
Parkinsonism & Related Disorders|July 25, 2013
Sleep and impulsivity in Parkinson's diseaseMichael K Scullin, Ann B Sollinger, Julia Land, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 21, 2023
Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and RecommendationsDavide Martino, Vikram Karnik, Roongroj Bhidayasiri, et al.
Frontiers in Neurology|November 30, 2016
A Functional Magnetic Resonance Imaging Study of Head Movements in Cervical DystoniaCecília N Prudente, Randall Stilla, Shivangi Singh, et al.
American Journal of Human Genetics|November 5, 2013
Association of Parkinson disease with structural and regulatory variants in the HLA regionWilliam T Wissemann, Erin M Hill-Burns, Cyrus P Zabetian, et al.
Parkinsonism & Related Disorders|December 3, 2020
A metabolomic study of cervical dystoniaChang Liu, Laura Scorr, Gamze Kilic-Berkmen, et al.
Journal of the Neurological Sciences|December 4, 2014
Cognitive correlates of hallucinations and delusions in Parkinson's diseaseStewart A Factor, Michael K Scullin, Ann B Sollinger, et al.
The Lancet. Neurology|December 11, 2019
Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 studyC Warren Olanow, Stewart A Factor, Alberto J Espay, et al.
Journal of Clinical Psychopharmacology|June 20, 2024
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Frontiers in Neurology|March 14, 2022
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension StudyRobert A Hauser, Hadas Barkay, Hubert H Fernandez, et al.
Annals of Neurology|December 26, 2006
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patientsDenise M Kay, Dawn Moran, Lina Moses, et al.
Pageof 20